Explore the potential of SGLT2 inhibitors for IgAN. Learn how these diabetes drugs slow kidney damage progression when added to standard treatment.

MADRID — Nearly half of people with type 2 diabetes (T2D) currently recommended to receive sodium-glucose cotransporter 2 (SGLT2) inhibitors for kidney protection would not actually benefit from them, ...

A fast-aging fish is giving scientists a rare, accelerated look at how kidneys grow old—and how a common drug may slow that ...

SGLT2 inhibitors prevented age-related kidney damage in a rapid-aging fish. Treatment preserved blood vessels, energy ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Nihar R. Desai, MD ...

SAN DIEGO -- Benefits with empagliflozin (Jardiance) for cardiovascular and renal health linger for about a year after discontinuation, as off-drug follow-up from the EMPA-KIDNEY trial showed. During ...

The SGLT2 inhibitor medicines have changed how heart failure is managed. Originally sodium-glucose cotransporter 2 (SGLT2) inhibitors were used to lower blood sugar levels in people who have type 2 ...

Uptake of sodium-glucose cotransporter 2 (SGLT2) inhibitors among US patients eligible for treatment according to clinical guidelines is extremely low, no matter their diabetes status, according to ...

CHICAGO -- SGLT2 inhibitor use was linked to reduced progression of in-situ pulmonary adenocarcinoma, an observational study showed. Nodule growth over the median 28 months of follow-up was 62% less ...